The trial, sponsored by the University of Utah, aims to evaluate a novel non-invasive therapeutic approach for Alzheimer's disease, a condition with significant unmet medical need and a growing market. The use of low-intensity ultrasound for cognitive impairment may position the Diadem prototype as a competitive alternative to existing pharmacological treatments, particularly if it demonstrates efficacy in improving cognitive outcomes. The Alzheimer's disease market is projected to reach $20 billion by 2025, highlighting the commercial potential of successful interventions. However, the termination of this trial due to IRB administrative closure raises concerns regarding regulatory compliance and operational viability, necessitating further diligence on the sponsor's capacity to navigate these challenges.